Global Plasma Fractionation Market Expected to Reach XX Million by 2025

2018-03-09 19:28:01

According to a new report published by Reports Monitor titled, “Plasma Fractionation Market by product, by application, and by end user: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the Plasma Fractionation market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. North America dominates the Plasma Fractionation market, in terms of value, and is expected to maintain this trend throughout the forecast period. 

Application of plasma fractionation in preventing and treating of life threatening diseases caused by immunologic disorders, trauma and infection are creating demand and fuel to growth of the market.

Get a Sample PDF Report @

Furthermore, plasma usage in the production of packaging material for industrial application and its demand in therapeutic area for treating protein deficiencies fuelling the market for further growth.  

However, stringent government regulations, high cost and limited reimbursement are hampers growth of the market.

• Protease inhibitor segment in products is expected to grow at higher rate as rise in prevalence of respiratory diseases.
•  By application segment neurology is accounted for largest share in the market.
• Hospitals and clinics are the major user of this market and accounted for highest share.
• North America dominates the plasma fractionation market followed by Europe and Asia Pacific.

The major companies profiled in the report include CSL, Octapharma AG, Grifols S.A, Kedrion S.p.A, Shire, Bio Product Laboratory, Sanquin, Biotest, LFB, and Japan Blood Products Organization.

About Garner Insights:
We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us
Kevin Thomas
+1 513 549 5911 (US)
+44 203 318 2846 (UK)

Related Press Releases